CagriSema vs Dulaglutide
A side-by-side research comparison of CagriSema and Dulaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Dulaglutide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Dulaglutide (Trulicity) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Prescription medication (FDA-approved) |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Activates GLP-1 receptors in pancreatic beta cells (enhancing glucose-dependent insulin secretion), the hypothalamus (reducing appetite), and the GI tract (slowing gastric emptying). The Fc fusion extends half-life to ~5 days. |
| Molecular weight | Combination product | ~63,000 Da |
| Half-life | 7 days (both components) | ~5 days (supports weekly dosing) |
| Bioavailability | High (SubQ) | ~65% subcutaneous |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 0.75 mg - 4.5 mg once weekly |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection (pre-filled pen) |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Dulaglutide reported benefits
- Significant weight loss (3-5% at standard doses)
- Improved glycemic control
- Reduced cardiovascular events (REWIND trial)
- Once-weekly convenience
- Appetite suppression
Related comparisons
Research and educational reference only. Not medical advice.